JOHNSON & JOHNSON | 2013 | FY | 3

Selected unaudited quarterly financial data for the years 2013 and 2012 are summarized below:
 
 
2013
 
2012
(Dollars in Millions Except Per Share Data)
 
First Quarter (1)
 
Second Quarter (2)
 
Third Quarter (3)
 
Fourth Quarter (4)
 
First Quarter (5)
 
Second Quarter (6)
 
Third Quarter (7)
 
Fourth Quarter (8)
Segment sales to customers
 
 

 
 

 
 

 
 

 
 

 
 

 
 

 
 

Consumer
 
$
3,675

 
3,658

 
3,611

 
3,753

 
3,595

 
3,619

 
3,581

 
3,652

Pharmaceutical
 
6,768

 
7,025

 
7,036

 
7,296

 
6,133

 
6,291

 
6,402

 
6,525

Med Devices & Diagnostics
 
7,062

 
7,194

 
6,928

 
7,306

 
6,411

 
6,565

 
7,069

 
7,381

Total sales
 
17,505

 
17,877

 
17,575

 
18,355

 
16,139

 
16,475

 
17,052

 
17,558

Gross profit
 
11,951

 
12,388

 
12,231

 
12,400

 
11,224

 
11,332

 
11,455

 
11,555

Earnings before provision for taxes on income
 
4,261

 
4,793

 
3,667

 
2,750

 
5,045

 
2,035

 
3,595

 
3,100

Net earnings attributable to Johnson & Johnson
 
3,497

 
3,833

 
2,982

 
3,519

 
3,910

 
1,408

 
2,968

 
2,567

Basic net earnings per share attributable to Johnson & Johnson
 
$
1.25

 
1.36

 
1.06

 
1.25

 
1.43

 
0.51

 
1.08

 
0.93

Diluted net earnings per share attributable to Johnson & Johnson
 
$
1.22

 
1.33

 
1.04

 
1.23

 
1.41

 
0.50

 
1.05

 
0.91


(1)
The first quarter of 2013 includes after-tax charges of $183 million from Synthes integration/transaction costs, $391 million from net litigation expense and $42 million from impairment of in-process research and development, and $30 million associated with the DePuy ASR™ Hip program.
(2) 
The second quarter of 2013 includes after-tax charges of $308 million from net litigation expense, $87 million from Synthes integration/transaction costs and $61 million associated with the DePuy ASR™ Hip program.
(3) 
The third quarter of 2013 includes after-tax charges of $720 million from net litigation expense, $103 million from Synthes integration/transaction costs, $126 million from impairment of in-process research and development and $31 million associated with the DePuy ASR™ Hip program.
(4) 
The fourth quarter of 2013 includes after-tax charges of $227 million from net litigation expense, $110 million from Synthes integration/transaction costs, $294 million from impairment of in-process research and development, $118 million associated with the DePuy ASR™ Hip program and a $707 million tax benefit associated with Scios Inc.
(5) 
The first quarter of 2012 includes an after-tax gain of $106 million from currency and costs associated with the acquisition of Synthes, Inc.
(6) 
The second quarter of 2012 includes after-tax charges of $717 million for asset write-downs, $611 million from net litigation expense, $564 million associated with the acquisition of Synthes, Inc. and $344 million from impairment of in-process research and development.
(7) 
The third quarter of 2012 includes after-tax charges of $135 million associated with the acquisition of Synthes, Inc., $340 million from impairment of in-process research and development, $70 million associated with net litigation expense, and $24 million associated with the DePuy ASR™ Hip program.
(8) 
The fourth quarter of 2012 includes after-tax charges of $371 million from net litigation expense, $306 million associated with the acquisition of Synthes, Inc., $73 million associated with the DePuy ASR™ Hip program and $59 million from impairment of in-process research and development.

us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock